Last reviewed · How we verify
Chengdu Brilliant Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| BT-KTM-I | BT-KTM-I | phase 3 | PDE3 inhibitor | PDE3 | Cardiovascular | |
| Ketanest®S | Ketanest®S | phase 3 | NMDA receptor antagonist; dissociative anesthetic | NMDA receptor (N-methyl-D-aspartate receptor) | Anesthesiology |
Therapeutic area mix
- Anesthesiology · 1
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Chengdu Brilliant Pharmaceutical Co., Ltd.:
- Chengdu Brilliant Pharmaceutical Co., Ltd. pipeline updates — RSS
- Chengdu Brilliant Pharmaceutical Co., Ltd. pipeline updates — Atom
- Chengdu Brilliant Pharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Chengdu Brilliant Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chengdu-brilliant-pharmaceutical-co-ltd. Accessed 2026-05-17.